AM-Pharma Announces Appointment of Russell Greig as Chairman
2012-01-04
AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and Inflammatory bowel diseases, today announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board.
AM-Pharma Raises €29.2m in Series D Financing
2011-09-13
- This fundraising will enable AM-Pharma to advance its human recombinant form of human AP from preclinical stages through to the end of phase II as a treatment for Acute Kidney Injury (AKI).
- The series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners and supported by a consortium including the venture arms of two global Healthcare companies, Abbott and Shire, the European venture funds, BB Biotech Ventures and Idinvest Partners as well as existing investors, Forbion Capital Partners and Inventages Venture Capital.
Erik van den Berg, AM-Pharma:"Inventages has a broad network of excellent service providers and experts and can provide board room access with potential strategic partners."
